CRT 2026: Key Takeaways for Interventional Cardiologists

Why It Matters

The findings directly influence clinical decision‑making, offering evidence‑based pathways to improve patient outcomes, procedural safety, and cost efficiency across cardiology practices.

Key Takeaways

• TAVR and SAVR show similar 7‑year outcomes
• ERPDs cut staff radiation, enable lighter aprons
• Orbital atherectomy not superior to balloon angioplasty
• Sirolimus DEB non‑inferior, reduces stent need
• Clopidogrel monotherapy outperforms aspirin after 12‑month DAPT

Pulse Analysis

The CRT 2026 conference delivered a pivotal update on transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in low‑risk patients. The seven‑year PARTNER 3 substudy confirms that while TAVR provides an early health‑status advantage, both modalities converge on similar long‑term outcomes. This parity supports broader adoption of TAVR in eligible populations, potentially reducing surgical resource utilization and accelerating recovery timelines.

Radiation exposure remains a critical safety concern in cath‑lab environments. Data from a 135‑case series demonstrated that enhanced radiation protection devices (ERPDs) dramatically lower scatter doses, allowing operators to consider ultralight or even lead‑free aprons without compromising occupational safety thresholds. This advancement not only improves ergonomics for interventionalists but also aligns with emerging regulatory emphasis on dose‑reduction strategies.

Therapeutic innovations also took center stage. The ECLIPSE trial showed orbital atherectomy offers no clear benefit over conventional balloon angioplasty for lesion preparation, prompting a reassessment of routine atherectomy use. Conversely, the SELUTION trial highlighted sirolimus drug‑eluting balloons as a non‑inferior alternative to drug‑eluting stents, achieving comparable target‑vessel failure rates while sparing 80% of patients from permanent implants. Meanwhile, clopidogrel monotherapy demonstrated superior efficacy to aspirin after one year of dual antiplatelet therapy, suggesting a shift toward personalized antiplatelet regimens. Together, these insights equip interventional cardiologists with data‑driven options to refine procedural tactics, enhance patient safety, and optimize long‑term cardiovascular care.